Welcome to the HCV Advocate’s AASLD Conference coverage.  In an effort to best serve our readership, we will post all the important and interesting abstracts about HCV from the conference.  While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.  The other abstracts posted to the web site are HCV related abstracts posted to www.aasld.org that we have not been able to report on or update.  

 

To locate specific abstracts on this page, click on “Edit” at the top of  your browser (Microsoft Internet Explorer) and then on Find (on this page).  In Netscape, click on “Search” and then on “Find in This Page.” Simply type in a word or term and the search engine will list the related abstracts.

 

Please click here to view our fact sheet on reading and understanding an abstract.

 

Thank You,

Alan Franciscus

Editor-in-Chief

 

 

 

 

 

Hepatitis C

 

 

Drugs in Development

Studies on the new therapies being investigated to treatment hepatitis C that have been studied in humans, but have not been approved by the FDA.

 

·       Albuferon

o      A PHASE 2 STUDY OF ALBUFERON IN COMBINATION WITH RIBAVIRIN INNON-RESPONDERS TO PRIOR INTERFERON THERAPY FOR CHRONIC HEPATITIS C. (updated November 16, 2005)

 

·       Amantadine

o      MUTATIONS IN THE HCV-P7 PROTEIN AND SENSITIVITY TO ANTIVIRAL THERAPY WITH AMANTADINE IN CHRONIC HEPATITIS C.

o      DOES AMANTADINE IMPROVE THE VIROLOGICAL SUSTAINED RESPONSE OF NAÏVE PATIENTS WITH CHRONIC HEPATITIS C IN ASSOCIATION WITH PEG-INTERFERON-RIBAVIRIN COMBINATION ? A PROSPECTIVE, RANDOMISED, MULTICENTER, DOUBLE-BLIND STUDY:PRELIMINARY RESULTS IN 200 PATIENTS. (updated November 26, 2005)

·       CPG 10101

o       IMMUNOPHENOTYPING PROFILE OF CPG 10101, A NEW TLR9 AGONIST ANTIVIRAL FOR HEPATITIS C.

 

·       GNS 037

o       ENTRY INHIBITOR GNS 037 EXHIBITS POTENT ANTI-HCV ACTIVITY IN VITRO

 

·       Gamma Interferon

o      ANALYSIS OF RESPONSES TO ALPHA AND GAMMA INTERFERONS IN HEPATITIS C VIRUS INFECTED CHIMPANZEES.

o      CONSENSUS INTERFERON IN COMBINATION WITH GAMMA INTERFERON AND/OR RIBAVIRIN LEADS TO A SIGNIFICANT RESPONSE IN TREATMENT-NAIVE HEPATITIS C GENOTYPE 1 PATIENTS. (updated November 28, 2005)

 

·       NM283

o      CHARACTERIZATION OF NM283 (VALOPICITABINE) RESISTANCE PROFILE USING BOVINE VIRAL DIARRHEA VIRUS.

o      ABSENCE OF EFFECT OF PEGYLATED INTERFERON ALFA-2B ON THE PHARMACOKINETICS OF VALOPICITABINE (NM283) IN PATIENTS WITH CHRONIC HEPATITIS C. (updated November 14, 2005)

o      RANDOMIZED TRIAL OF VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, VS. RETREATMENT WITH PEG-INTERFERON PLUS RIBAVIRIN (PEGIFN/RBV) IN HEPATITIS C PATIENTS WITH PREVIOUS NON-RESPONSE TO PEGIFN/RBV: FIRST INTERIM RESULTS. (updated November 18, 2005)

 

·       R1479 

o      HIGH SELECTIVITY AND LOW CYTOTOXICITY ASSOCIATED WITH R1479, A NOVEL INHIBITOR OF HCV REPLICATION.

o      THE NOVEL NUCLEOSIDE ANALOG R1479 IS A POTENT INHIBITOR OF HCV POLYMERASE AND HCV REPLICATION IN CELL CULTURE.

 

·       SCH 503034

o      ANTI-VIRAL ACTIVITY OF SCH 503034, A HCV PROTEASE INHIBITOR, ADMINISTERED AS MONOTHERAPY IN HEPATITIS C GENOTYPE-1 (HCV-1) PATIENTS REFRACTORY TO PEGYLATED INTERFERON (PEG-IFN-Á). (updated November 18, 2005)

o      COMBINATION THERAPY WITH THE HCV PROTEASE INHIBITOR, SCH 503034, PLUS PEG-INTRON INHEPATITIS C GENOTYPE-1 PEG-INTRON NON-RESPONDERS: PHASE IB RESULTS. (updated November 18, 2005)

 

·       VX-950

o      DECLINE IN SERUM NEOPTERIN CONCENTRATION CORRELATES WITH HCV RNA DECLINE DURING ADMINISTRATION OF VX-950, A HEPATITIS C VIRUS PROTEASE INHIBITOR.

o      PRECLINICAL AND EARLY CLINICAL DEVELOPMENT GENETIC HETEROGENEITY IN THE HCV NS3 PROTEASE OF UNTREATED GENOTYPE 1 PATIENTS HAS LITTLE EFFECT ON THE SENSITIVITY TO VX-950.

o      ITMN A AND B, NOVEL INHIBITORS OF THE HCV NS3/4 PROTEASE RETAIN THEIR POTENCY AGAINST VX-950 AND BILN-2016 RESISTANT NS3/4 PROTEASE MUTANTS AND AN IFN-A-2A RESISTANT HCV REPLICON. (updated November 14, 2005)

o      FINAL RESULTS OF A PHASE 1B, MULTIPLE-DOSE STUDY OF VX-950, A HEPATITIS C VIRUS PROTEASE INHIBITOR. (updated November 17, 2005)

o      PHARMACOKINETICS OF VX-950, AND ITS EFFECT ON HEPATITIS C VIRAL DYNAMIC (updated November 17, 2005)

 

Drugs in Development – Preclinical

Drugs that are being designed and tested to treat hepatitis C, but have not been studied in humans.

 

·       THERAPEUTIC VACCINATION FOR CHRONIC HEPATITIS C VIRUS INFECTION IN HCV TRIMERA MICE

·       DEMONSTRATION OF THE EFFICACY OF SMALL MOLECULE HCV INHIBITORS IN THE KMT MOUSEMODEL OF HEPATITIS C VIRUS (HCV) INFECTION.

·       PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE ISATORIBINE ORAL PRODRUG ANA975 IN APHASE 1 HEALTHY VOLUNTEER STUDY. (updated November 28, 2005)

·       REDIRECTING T LYMPHOCYTE SPECIFICITY USING HCV-SPECIFIC T CELL RECEPTOR GENES CONFERS RECOGNITION OF NATURALLY OCCURRINGVIRAL MUTANTS.

·       SINGLE DOSE PHARMACOKINETICS OF A NOVEL HEPATITIS C PROTEASE INHIBITOR, SCH 503034, IN AN ORAL CAPSULE FORMULATION.

·       DEVELOPMENT IDENTIFICATION OF A NOVEL SMALL MOLECULE HEPATITIS C VIRUS REPLICATION INHIBITOR THAT TARGETS HOST SPHINGOLIPID BIOSYNTHESIS.

·       DEVELOPMENT SCH 503034, A MECHANISM-BASED INHIBITOR OF HEPATITIS C VIRUS (HCV) NS3 PROTEASE SUPPRESSES POLYPROTEIN MATURATION AND ENHANCES THE ANTIVIRAL ACTIVITY OF INTERFERON-Á-2B (INF)

·       HCV REPLICATION IS INHIBITED BY CYCLOSPORIN A, MYCOPHENOLIC ACID AND IFN-ALPHA IN A SYNERGISTIC FASHION AND WITH DISTINCT ANTI-VIRAL KINETICS.

·       NIM811 EXHIBITS POTENT ANTI-HCV ACTIVITY IN VITRO AND REPRESENTS A NOVEL APPROACH FOR VIRAL HEPATITIS C THERAPY.

·       CANNABINOIDS BLOCK INTERFERON-MEDIATED SUPPRESSION OF HEPATITIS C VIRUS (HCV) REPLICATION. (updated November 14, 2005)

·       THE IMMUNOMODULATOR AS101 INHIBITS HCV REPLICATION. (updated November 14, 2005)

·       CHARACTERIZATION OF IN VITRO SELECTED CON 1 SUBGENOMIC REPLICONS RESISTANT TO 2’-CMETHYL-CYTIDINE, A POTENT INHIBITOR OF GENOTYPE 1A AND 1B HCV POLYMERASES.

·       AN Á-GLUCOSIDASE INHIBITOR APPROVED FOR USE IN TYPE II DIABETES HAS ANTIVIRAL ACTIVITY AND DISPLAYS SYNERGY WITH IFN ALFACON-1 IN A SURROGATE SYSTEM FOR HCV.  (updated November 22, 2005)

·       TREATMENT OF HCV-ASSOCIATED PROGRESSIVE LIVER DISEASE WITH TACROLIMUS: TRIAL USING A MOUSE MODEL. (updated November 14, 2005)

·       CHARACTERIZATION OF A NOVEL APPROACH FOR HCV IMMUNIZATIONUSING SPLENIC DERIVED DENDRITIC CELLS WITH PHAGOCYTOSED HCVNS5 COATED MAGNETIC BEADS.

 

 

Drugs in Development – Phase 3, 4 Trials

Drugs that have been FDA approved to treat hepatitis C and have undergone additional testing in special populations and circumstances.

 

·       SHORT-TERM TREATMENT DURATION FOR HCV-2 AND HCV-3 INFECTED PATIENTS WITH CHRONIC HEPATITIS. (updated November 28, 2005

·       PEG-IFN ALPHA2B AND RIBAVIRIN IN DECOMPENSATED CIRRHOTIC PATIENTS WITH CHRONIC HCV INFECTION: A CONTROLLED STUDY.

·       SUSTAINED VIROLOGIC RESPONSE RATES FROM A RANDOMIZED TRIAL OF HCV GENOTYPE-1 SUBJECTS TREATED WITH EITHER CONSENSUS IFN AND RIBAVIRIN OR PEGYLATED INTERFERON ALFA-2B AND RIBAVIRIN.

·       A STUDY ON THE TREATMENT OF CHRONIC HCV HEPATITIS WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN HAEMODIALYZED PATIENTS WAITING FOR RENAL TRANSPLANT.

·       FIBROSIS STAGE IS NOT A PREDETERMINANT OF SIGNIFICANT ADVERSE EVENTS IN PREVIOUS INTERFERON (IFN)-RIBAVIRIN (RIBA) TREATMENT FAILURES RECEIVING PEG-INTERFERON-ALFA 2B/RIBA WEIGHT BASED DOSING: RESULTS FROM THE EPIC3 PROGRAM. (updated November 28, 2005

·       INTERFERON (IFN) INDUCED THROMBOCYTOPENIA IS INDEPENDENT OF LEVEL OF FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C (CHC): RESULTS FROM THE EPIC3 PROGRAM.

·       MINIMAL IMPORTANT DIFFERENCE (MID) IN VITALITY SCORE; A NEW OUTCOME MEASURE IN HCV TREATMENT TRIALS.

·       INTERIM ANALYSIS OF THE SAFETY AND EFFICACY OF PEGINTERFERON ALFA-2A PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS UNABLE TO TOLERATE OR NONRESPONSIVE TO TREATMENT WITH PEGINTERFERON ALFA-2B PLUS RIBAVIRIN  (updated November 21, 2005)

·       WEIGHT-BASED RIBAVIRIN DOSING (WBD) INCREASES SUSTAINED VIRAL RESPONSE (SVR) INPATIENTS WITH CHRONIC HEPATITIS C (CHC): FINAL RESULTS OF THE WIN-R STUDY, A US COMMUNITY BASED TRIAL. (updated November 21, 2005)

 

 

HCV Medications Approved by the FDA

Studies about the medications approved or indicated to treat hepatitis C.  In addition, issues such as retreatment, refining treatment issues, and treatment in special populations are listed in this section. 

 

·       Infergen (consensus interferon)

o      CONSENSUS INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE NONRESPONDERS TO PRIOR THERAPY WITH EITHER INTERFERON ALFA AND RIBAVIRIN OR PEGYLATED INTERFERON AND RIBAVIRIN.

o      EARLY VIRAL RESPONSE TO CONSENSUS INTERFERON PLUS RIBAVIRIN THERAPY IN PATIENTS WHO ARE NONRESPONDERS OR RELAPSERS TO PRIOR PEG IFN PLUS RIBAVIRIN THERAPY.

o      EFFICACY OF DAILY CONSENSUS INTERFERON AND RIBAVIRIN COMPARED TO PEG-INTERFERON Á-2B AND RIBAVIRIN IN NON-RESPONDERS WITH CHRONIC HEPATITIS C.

o      PEGYLATED INTERFERONS (PEG-IFNS) DO NOT PRESENT VIRAL REBOUND AFTER SHORT-TERM ADMINISTRATION OF CONSENSUS INTERFERON (CIFN) TO IFN-NAIVE PATIENTS (PTS) WITH CHRONIC HEPATITES C (CHC), GENOTYPE 1.

o      EFFICACY AND COST-EFFECTIVENESS OF 24 WEEKS OF HIGH-DOSE INDUCTION THERAPY WITH CONSENSUS INTERFERON IN CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 2 INFECTION.

o      ANTIVIRAL RESPONSE OF HCV GENOTYPE-1 TO CONSENSUS INTERFERON AND RIBAVIRIN COMPARED WITH PEGYLATED INTERFERON AND RIBAVIRIN. (updated November 22, 2005

 

·       Pegasys (peginterferon alfa-2a)

o      SUSTAINED VIROLOGICAL RESPONSE (SVR) IS DURABLE AFTER TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) ALONE OR IN COMBINATION WITH RIBAVIRIN (COPEGUS®): RESULTS OF AN ONGOING LONG-TERM FOLLOW-UP STUDY. (updated November 16, 2005)

o      EFFECT OF ETHNICITY ON THE PHARMACOKINETICS OF RIBAVIRIN (COPEGUS®) AND PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) IN PATIENTS WITH CHRONIC HEPATITIS C.

o      ASSOCIATION BETWEEN SUSTAINED VIROLOGICAL RESPONSE (SVR) AND ALT LEVELS IN HIV-HCV CO-INFECTED PATIENTS WHO RECEIVED PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN THE AIDS PEGASYS RIBAVIRIN INTERNATIONAL CO-INFECTION TRIAL (APRICOT). (updated November 26, 2005) 

o      INTERIM SAFETY ANALYSIS OF PATIENTS ENROLLED IN THE RANDOMIZED, INTERNATIONAL RETREATMENT WITH PEGASYS® IN PATIENTS NOT RESPONDING TO PRIOR PEGINTERFERON ALFA-2B/RIBAVIRIN (RBV) COMBINATION THERAPY (REPEAT) STUDY.  (updated November 28, 2005)

o      PHARMACOKINETICS AND RESPONSE OF OBESE PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH DIFFERENT DOSES OF PEG-IFN ALPHA2A(40KD) (PEGASYS®).  (updated November 26, 2005) 

o      VIRAL AND METABOLIC FACTORS INFLUENCING ALANINE AMINOTRANSFERASE (ALT) ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C RECEIVING PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN RANDOMIZED PHASE III TRIALS.  (updated November 26, 2005) 

o      ARE THERE DIFFERENCES IN SUSTAINED VIROLOGICAL RESPONSE (SVR)RATES IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND PERSISTENTLY ‘NORMAL’ ALT ACTIVITY UNDERGOING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®)? 

o      IMPACT OF BASELINE HEPATITIS C VIRUS (HCV) RNA AND GENOTYPE ON THE EFFICACY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN PATIENTS WITH COMPENSATED CIRRHOSIS/BRIDGING FIBROSIS. (updated November 17, 2005) 

o      FASTING TRIGLYCERIDE LEVELS BEFORE, DURING AND AFTER TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) IN PATIENTS INFECTED WITH HCV GENOTYPE 2 OR 3: THE ACCELERATE SERUM TRIGLYCERIDE SUBSTUDY. (updated November 21, 2005)   

o      CLUSTERING OF POOR PROGNOSTIC FACTORS IN HEAVIER PATIENTS WITH CHRONIC HEPATITIS C (CHC): BASELINE CHARACTERISTICS AND OUTCOMES WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) IN RANDOMIZED, INTERNATIONAL, PHASE III TRIALS. (updated November 15, 2005)  

o      PREDICTED OUTCOMES IN PATIENTS WITH PERSISTENTLY ‘NORMAL’ ALT LEVELS AND HCV GENOTYPE 1 TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) 1000/1200 MG/DAY FOR 48 WEEKS.  (updated November 17, 2005)

o      EFFICACY OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C IN GERMANY – A CONTRIBUTION TO HEALTH CARE RESEARCH.  (updated November 18, 2005)

o      WEEK 4 VIROLOGICAL RESPONSE WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) PORTENDS A SUSTAINED VIROLOGICAL RESPONSE (SVR) AFTER 24 WEEKS IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS WITH PERSISTENTLY ‘NORMAL’ ALT ACTIVITY. (updated November 26, 2005)

o      AN EVALUATION OF THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) FOR THE FIRST TREATMENT OF MILD CHRONIC HEPATITIS C (CHC). (updated November 26, 2005)

o      LOW BODY WEIGHT PREDICTS PEG-INTERFERON ALFA-2A (PEGASYS) INDUCED NEUTROPENIA IN CHRONIC HEPATITIS C PATIENTS.

o      IS SHORTER TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) POSSIBLE IN HCV GENOTYPE 1 ‘SUPER-RESPONDERS’? PRELIMINARY RESULTS OF A PROSPECTIVE RANDOMIZED CLINICAL TRIAL.

o      RAPID VIROLOGICAL RESPONSE AT WEEK 4 (RVR) OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) TREATMENT PREDICTS SUSTAINED VIROLOGICAL RESPONSE (SVR) AFTER 24 WEEKS IN GENOTYPE 1 PATIENTS. (updated November 15, 2005)

 

·       Peg-Intron (peginterferon alfa-2b)

o      PEG-IFN ALPHA 2B (1.5 MCG/KG/WK) + RIB (800-1400 MG DAILY) IS SIGNIFICANTLY MORE EFFECTIVE THAN PEG-IFN ALPHA 2B (1.0 MCG/KG/WK) + RIB (800-1400 MG DAILY) IN MEN WITH GT 1 AND WOMEN WITH GT 2/3: FINAL RESULTS OF A PROSPECTIVE, RANDOMIZED, CONTROLLED TRIAL. 

o      PEGINTERFERON A-2B 1 MCG/KG DOSE PLUS RIBAVIRIN 800-1200MG FOR 24-48 WEEKS, ACCORDING TO GENOTYPE, IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C: EFFICACY AND COST-EFFECTIVENESS EVALUATION. (updated November 15, 2005)

o      COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C IN HIV-HCV CO-INFECTED PATIENTS. 

o      THE TARGET TRIAL: FINAL RESULTS USING 3.0ΜG/KG PEGYLATED INTERFERON ALFA 2-B (PEG;PEG-INTRON®) PLUS RIBAVIRIN (RBV;REBETOL®) FOR CHRONIC HEPATITIS C PATIENTS WHO WERE NONRESPONDERS (NR) AND RELAPSERS (R) TO PREVIOUS THERAPY. 

o      DIFFERING IMMUNE EFFECTS OF PEG-IFN-ALPHA 2B AND IFN-ALPHA 2B COMBINED WITH RIBAVIRIN FOR CHRONIC HEPATITIS C. 

o      PEGINTERFERON-A 2B AND RIBAVIRIN TREATMENT IN PATIENTS WITH HEPATITIS C VIRUS-RELATED SYSTEMIC VASCULITIS.

o      DOUBLE-DOSE PEGINTERFERON ALFA-2B WITH WEIGHT-BASED RIBAVIRIN IMPROVES RESPONSE FOR INTERFERON/RIBAVIRIN NON-RESPONDERS WITH HEPATITIS C: FINAL RESULTS OF “RENEW”.

o      CLINICAL AND ECONOMIC IMPLICATIONS OF A 4-WEEK VIRAL NEGATIVE RESPONSE TO PEGINTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C AND GENOTYPE 1 WITH LOW VIRAL LOAD. 

o      THE ANTIVIRAL EFFECTS ASSESSED BY INTERFERON INDUCED ENZYME, 2_F-5F OLIGOADENYLATE SYNTHETASE (2-5AS) ACTIVITY DURING INTERFERON ALPHA 2B+RIBAVIRAN, PEGINTERFERON ALPHA 2A ALONE, AND PEGINTERFERON ALPHA 2B+RIBAVIRIN THERAPIES FOR CHRONIC HEPATITIS C.

o      TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PEGINTERFERON ALFA-2B (PEGIFN), HIGH WEIGHT BASED DOSE RIBAVIRIN (RVN) AND EPOETIN ALFA (EPO) ENHANCES SUSTAINED VIROLOGIC RESPONSE (SVR). (updated November 26, 2005)

o      PEGINTERFERON A-2B 1 MCG/KG DOSE PLUS RIBAVIRIN 800-1200MG FOR 24-48 WEEKS, ACCORDINGTO GENOTYPE, IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C: EFFICACY AND COST-EFFECTIVENESS EVALUATION. (updated November 26, 2005)

o      INTERFERON (IFN) INDUCED THROMBOCYTOPENIA IS INDEPENDENT OF LEVEL OF FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C (CHC): RESULTS FROM THE EPIC3 PROGRAM. (updated November 28, 2005)

o      PEGETRON PROSPECTIVE OPTIMAL WEIGHT-BASED DOSING RESPONSE PROGRAM (POWER): PRELIMINARY RESULTS. (updated November 28, 2005) 

 

·        Ribavirin

o      TOTAL CLEARANCE OF RIBAVIRIN (CL/F) BASED RIBAVIRIN DOSAGE IMPROVES THE SAFETY AND EFFECT OF INTERFERON AND RIBAVIRIN COMBINATION THERAPY FOR CHRONIC HEPATITIS C.

o      ASSESSMENT OF RIBAVIRIN MUTAGENIC PROPERTIES IN VIVO AND THE INFLUENCE OF INTERFERON ALPHA-INDUCED REDUCTION OF HEPATITIS C VIRUS RNA LOAD UPON THERAPY.

o      EVIDENCE OF SATURABLE RIBAVIRIN ABSORPTION.

o      RIBAVIRIN PLASMA CONCENTRATION IS PREDICTIVE OF SUSTAINED VIROLOGICAL RESPONSE IN HCV INFECTED PATIENTS. A PROSPECTIVE STUDY.

o      WEIGHT BASED RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA 2-B DOES NOT IMPROVE SVR IN HCV INFECTED PATIENTS WHO FAILED PRIOR THERAPY: RESULTS IN 454 PATIENTS.

 

 

Treatment Issues

Other treatment related issues such as side effect management, the use of adjunct or supportive therapies, predictors of treatment response  and so forth

 

·       General

o      PATHOGENETIC SIGNIFICANCE OF NEUTRALIZING ANTI-HCV ANTIBODIES IN ACUTE AND CHRONIC HEPATITIS C VIRUS (HCV) INFECTION OFCHIMPANZEES TREATED WITH HYPERIMMUNE ANTI-HCV (CIVACIR™).

o      ASSOCIATION OF A SINGLE NUCLEOTIDE POLYMORPHISM OF THE CTLA-4 GENE WITH RESPONSE TO INTERFERON-BASED TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION.

o      SPECIFIC MECHANISMS OF HCV-3 ON HYPOCHOLESTEROLEMIA. LONG-TERM EFFECT OF SUSTAINED VIROLOGICAL RESPONSE.

o      SOLUBLE INTERLEUKIN 2 RECEPTORS PLASMA LEVELS AMONG RESPONDER AND NON-RESPONDER PATIENTS WITH CHRONIC HEPATITIS C.

o      A SIGNIFICANT ASSOCIATION OF THE SUBSTITUTION IN POSITION 2209 OF NS5A OF HEPATITIS C VIRUS 1B INFECTION AND THE RESPONSE TO STANDARD, CONSENSUS, OR PEGYLATED INTERFERON PLUS RIBAVIRIN THERAPY.

o      PRIMARY CARE BASED HEPATITIS C TREATMENT: COLLABORATING TO IMPROVE ACCESS, ADHERENCE AND OUTCOMES.

o      THE ASSOCIATION OF FATIGUE WITH POOR VIROLOGIC RESPONSE IN PATIENTS RECEIVING INTERFERON ALPHA PLUS RIBAVIRIN FOR THE TREATMENT OF HEPATITIS C.

o      INCIDENCE OF INFECTIONS DURING COMBINATION TREATMENT OF CHRONIC HEPATITIS C WITH PEGYLATED INTERFERONS ALFA 2B and 2A.

o      BASELINE NEUTRALIZING RESPONSES PREDICT THE VIROLOGICAL RESPONSE TO PEGYLATED INTERFERON ALPHA-RIBAVIRIN COMBINATION THERAPY.

o      EXPECTANT MANAGEMENT OF CHRONIC HEPATITIS C INFECTION – THE PATIENT PERSPECTIVE.

o      PERIPHERAL INSULIN RESISTANCE DURING THE TREATMENT OF CHRONIC C HEPATITIS WITH PEGYLATED INTERFERON PLUS RIBAVIRIN.

o      INFLUENCE OF APOLIPOPROTEIN E GENOTYPE ON VIROLOGIC RESPONSE IN HCV TYPE 1-INFECTED PATIENTS TREATED WITH PEG-IFNA PLUS RIBAVIRIN

o      PREDICTIVE FACTORS FOR HISTOLOGICAL RESPONSE TO LONG-TERM PHLEBOTOMY IN PATIENTS WITH CHRONIC HEPATITIS C.

o      SOLUBLE INTERLEUKIN 2 RECEPTORS PLASMA LEVELS AMONG RESPONDER AND NON-RESPONDER PATIENTS WITH CHRONIC HEPATITIS C.

o      THE ROLE OF ANTIVIRAL THERAPY AFTER CHEMOTHERAPY ON THE CLINICAL OUTCOME OF HCV RELATED NON-HODGKIN LYMPHOMA (NHL).

o      ANTIVIRAL THERAPY IN PATIENTS WITH OCCULT HCV INFECTION.

o      RELATIONSHIP BETWEEN SUSTAINED VIRAL RESPONSE AND LEUKOCYTE INTERFERON RECEPTOR (IFNAR-2) EXPRESSION ON IN CHRONIC HEPATITIS C PATIENTS TREATED WITH SEVERAL INTERFERONS.

o      REDUCTION IN HEMOGLOBIN A1C VALUES IN DIABETIC PATIENTS DURING HEPATITIS C COMBINATION THERAPY: A COMBINED EFFECT OF RIBAVIRIN-INDUCED HEMOLYSIS AND DECREASED GLUCOSE LEVELS.

o      ANTIVIRAL COMBINATION THERAPY MODULATES SERUM LEVELS OF MARKERS OF HEPATIC ANGIOGENESIS IN CHRONIC HEPATITIS C (CHC) PATIENTS.

o      PEGYLATED INTERFERON PLUS RIBAVIRIN VERSUS NON-PEGYLATED INTERFERON PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C – A COCHRANE SYSTEMATIC REVIEW.

o      CYTOKINE RESPONSE IN CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGYLATED INTERFERON PLUS RIBAVIRIN.

o      ERYTHROPOIETIN INCREASES PLATELETS COUNT DURING ANTIVIRAL THERAPY WITH INTERFERON AND RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION.

o      THE INCREASE OF VON WILLEBRAND FACTOR AS A NEW PREDICTOR OF RESPONSE TO COMBINATION ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C.

o      ALTERATIONS OF LEPTIN LEVELS DURING IFN-Á TREATMENT IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C: EVIDENCE OF AN IFN-Á-MEDIATED SUPPRESSION OF LEPTIN PRODUCTION.

o      RELIABILITY AND VALIDITY OF THE BECK DEPRESSION INVENTORY (BDI-II) IN A CHRONIC HEPATITIS C POPULATION UNDERGOING PEG IFN PLUS RIBAVIRIN THERAPY

o      EFFECT OF SERTRALINE ON PRURITUS IN CHOLESTATIC LIVER DISEASE: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED CROSSOVER STUDY

o      TUMOR NECROSIS FACTOR ALPHA PROMOTER POLYMORPHISM AT POSITION ¡V308 PREDICTS HEPATITIS C VIRUS RESPONSE TO COMBINATION THERAPY WITH HIGH DOSE INTERFERON AND RIBAVIRIN.

o      SUSTAINED VIROLOGICAL RESPONSE TO TREATMENT IN 100% OF PATIENTS RECENTLY INFECTED, NOSOCOMIALLY, WITH HCV GENOTYPE 2.

 

·       African-Americans

o      PEGINTERFERON ALFA-2A AND RIBAVIRIN IN AFRICAN AMERICAN AND CAUCASIAN PATIENTS WITHCHRONIC HEPATITIS C, GENOTYPE 1.

o      PERSISTENCE WITH HEPATITIS C THERAPY IN AFRICAN AMERICANS AND PATIENTS WITH DEPRESSION IN THE DEPARTMENT OF VETERANS AFFAIRS (VA). (updated November 21, 2005)

o      COMPARISON OF AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENT SUSTAINED VIROLOGICRESPONSE IN PEG-IFN ALPHA 2 + WEIGHT-BASED RIBAVIRIN NONRESPONDERS RETREATED WITH IFN ALFACON-1 + IFN GAMMA-1B. (updated November 21, 2005)

 

·       Cirrhosis

o      VIRAL FACTORS INFLUENCE SVR IN PTS WITH HCV-RELATED BRIDGING FIBROSIS BUT NOT CIRRHOSIS.

o      PEG-INTERFERON ± RIBAVIRIN IN ADVANCED HCV CIRRHOSIS.

o      LOW RATES OF SUSTAINED VIROLOGICAL RESPONSE TO INTERFERON AND RIBAVIRIN THERAPY IN GENOTYPE 3 INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS.

o      SAFE USE OF PEG-IFN AND RIBAVIRIN IN HCV-CIRRHOTIC PATIENTS UNDERGOING PARTIAL SPLENIC EMBOLIZATION.

 

·       Genotype

o      PEGINTERFERON ALFA-2A AND RIBAVIRIN IN AFRICAN AMERICAN AND CAUCASIAN PATIENTS WITHCHRONIC HEPATITIS C, GENOTYPE 1.

o      SUSTAINED VIROLOGICAL RESPONSE TO TREATMENT IN 100% OF PATIENTS RECENTLY INFECTED, NOSOCOMIALLY, WITH HCV GENOTYPE 2.

o      TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PEGINTERFERON ALFA-2B(PEGIFN), HIGH WEIGHT BASED DOSE RIBAVIRIN (RVN) AND EPOETIN ALFA (EPO) ENHANCES SUSTAINED VIROLOGIC RESPONSE (SVR).

o      LOW RATES OF SUSTAINED VIROLOGICAL RESPONSE TO INTERFERON AND RIBAVIRIN THERAPY IN GENOTYPE 3 INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS.

 

·       IDU

o      DIRECTLY OBSERVED THERAPY (DOT) FOR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION IN INJECTION DRUG USERS (IDUS) – AN INTERIM ANALYSIS. (updated November 15, 2005)

o      ELIGIBILITY FOR TREATMENT OF HEPATITIS C VIRUS INFECTION AMONG YOUNG INJECTION DRUG USERS IN THREE US CITIES.

 

·        Steatosis

o      DOES HEPATIC STEATOSIS AFFECT SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C GENOTYPE 3 INFECTED PATIENTS?

 

·       Transplant

o      PATIENT SURVIVAL AND FIBROSIS PROGRESSION AFTER LIVER RETRANSPLANTATION FOR HEPATITIS CoINFECTION. (updated November 14, 2005)

o      NON INVASIVE ASSESSMENT OF LIVER GRAFT FIBROSIS BY TRANSIENT ELASTOGRAPHY AFTER LIVER TRANSPLANTATION.

o      RECURRENT HEPATITIS C VIRUS INFECTION AFTER LIVER TRANSPLANTATION AND CONCURRENT BILIARY TRACT COMPLICATIONS: POOR OUTCOME.

o      VIRAL QUASISPECIES AND SEVERITY OF RECURRENT HEPATITIS C.

o      PREDICTIVE FACTORS OF EARLY AND SUSTAINED VIRAL RESPONSE IN PATIENTS WITH RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION TREATED WITH COMBINED THERAPY (IFN-ALPHA AND RIBAVIRIN). (updated November 14, 2005)

o      MULTICENTER RANDOMIZED TRIAL OF HCV TREATMENT WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN AFTER LIVER TRANSPLANTATION:ONE-YEAR REPORT.

o      LONG TERM RESULTS AFTER THERAPY WITH PEGYLATED INTERFERON ALPHA 2A IN HCV POSITIVE LIVER TRANSPLANT RECIPIENTS (updated November 14, 2005)

o      ANTIVIRAL THERAPY FOR HCV-1B LIVER TRANSPLANT RECIPIENTS: BETTER RESULTS WITH YOUNGER GRAFTS.

o      ON TREATMENT VIROLOGICAL RESPONSE OF 70% IN 100 PATIENTS TREATED WITH COMBINATION ANTIVIRAL THERAPY FOR RECURRENT HCV FOLLOWING LIVER TRANSPLANTATION.

 

·       VA

o      PERSISTENCE WITH HEPATITIS C THERAPY IN AFRICAN AMERICANS AND PATIENTS WITH DEPRESSION IN THE DEPARTMENT OF VETERANS AFFAIRS (VA).

o      DIRECT COSTS OF MEDICAL CARE FOR TREATING HEPATITIS C PATIENTS IN A VETERANS AFFAIRS MEDICAL CENTER.

 

 

Diagnosis and Natural History

Data about diagnosing HCV including acute infection, special populations, disease progression in general and in special populations, extra-hepatic manifestations, and occult infection.

·       General

·       HEPATITIS C VIRUS PERSISTS AND REPLICATES IN THE LIVER OF THE MAJORITY OF SUSTAINED RESPONDER PATIENTS TO ANTIVIRAL TREATMENT.

·       DOES TREATMENT-INDUCED RECOVERY FROM HEPATITIS C RESULT IN THE SAME IMMUNOLOGICAL MEMORY AS SPONTANEOUS RECOVERY?

·       DIFFERENT CLINICAL PRESENTATION AND TREATMENT RESPONSE OF CHRONIC HEPATITIS C IN ASIAN AMERICANS VERSES NON-ASIAN AMERICANS.

·       TREATMENT OUTCOMES TO COMBINATION THERAPY IN PATIENTS WITH HCV GENOTYPE 6.

·       EARLY VIRAL KINETICS IN PATIENTS WITH CHRONIC HEPATITIS C AND END STAGE RENAL DISEASE DURING THERAPY WITH PEGINTERFERON ALFA-2A.

·       PERSISTENCE WITH HEPATITIS C THERAPY IN THE DEPARTMENT OF VETERANS AFFAIRS (VA).

·       INSULIN INCREASES HEPATITIS C VIRAL RNA REPLICATION IN CELL CULTURE.

·       GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY IS ASSOCIATED WITH SEVERE ANEMIA DURING INTERFERON AND RIBAVIRIN THERAPY.

·       RELEVANCE OF ADHERENCE IN THE TREATMENT OF ACUTE HEPATITIS C: FINAL RESULTS OF THE GERMAN HEP-HET ACUTE HEPATITIS C II TRIAL.

·       TIME IMPACT OF SERUM STORAGE TEMPERATURE ON STABILITY OF LIVER ENZYMES AND PROTEINS AND 0N FIBROTEST-ACTITEST RESULTS.

·       HISTOLOGIC PROGRESS IN PAIRED BIOPSIES BETWEEN 15TH AND 25TH YEARS AFTER A HEPATITIS C GENOTYPE 1B SINGLE SOURCE OUTBREAK IN GERMANY.

·       SPONTANEOUS FIBROSIS REGRESSION IN UNTREATED, NONCIRRHOTIC, PERSISTENTLY VIREMIC IRISH WOMEN WITH CHRONIC HEPATITIS C CONTRACTED INITIALLY FROM IMMUNOGLOBULIN ANTI-D: FINAL REPORT.  (updated November 15, 2005)

·       SPONTANEOUS HCV CLEARANCE IN PATIENTS FOLLOWED IN A HAEMOPHILA UNIT: EVALUATION OF CELLULAR IMMUNITY AGAINST HCV RECOMBINANT PROTEINS. (updated November 13, 2005)

·       DETERMINATION OF HEPATITIS C VIRUS(HCV)INFECTION STATUS IN SCREEN-REACTIVE DIALYSIS PATIENTS: WHAT IS THE BEST TESTING STRATEGY?.

·       HCV RNA QUANTIFICATION OF HCV GENOTYPES 1 TO 5: COMPARISON OF 4 DIFFERENT ASSAYS

·       EVIDENCE OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN PATIENTS WITH CHRONIC HEPATITIS C (HCV) INFECTION AND MINIMAL LIVER DISEASE. (updated November 13, 2005)

·       IMPACT OF HEPATITIS C VIRUS INFECTION AND OTHER COMORBIDITIES ON SURVIVAL IN PATIENTS ON DIALYSIS. (updated November 13, 2005)

·       ROLE OF MANNOSE-BINDING LECTIN (MBL2) POLYMORPHISMS IN THE DEVELOPMENT AND PROGRESSION OF CHRONIC LIVER DISEASE.

·       HCV RNA IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMNCS) OF SUSTAINED VIROLOGICAL RESPONDERS TO INTERFERON BASED THERAPIES: IS IT A RISK FOR RELAPSE? (updated November 13, 2005)

·       PROTEOMIC ANALYSIS OF SERUM PROTEINS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA ASSOCIATED WITH HEPATITIS C VIRUS INFECTION.

·       THE PERFORMANCE OF APRI FOR THE DIAGNOSIS OF SIGNIFICANT HEPATIC FIBROSIS IS IMPROVED BY A SIMPLE MODIFICATION.

·       INCREASED SURVIVAL OF PATIENTS WITH HCV-RELATED CIRRHOSIS WITH A LONG-TERM RESPONSE TO INTERFERON THERAPY.

·       DO SERUM AUTOANTIBODIES AFFECT THE SEVERITY OF CHRONIC HEPATITIS C.

·       THE SOURCE OF HCV DIAGNOSIS AFFECTS THE LONG-TERM COURSE OF CHRONIC HEPATITIS C (CHC).

·       LIVER STIFFNESS AND BIOMARKERS: CORRELATION WITH CIRRHOSIS,PORTAL HYPERTENSION AND HEPATIC SYNTHETIC FUNCTION.

·       PERSISTENCE OF HCV INFECTION IN APPARENTLY HEALTHY ANTI-HCV POSITIVE PATIENTS WITH CONSTANTLY SERUM HCV-RNA NEGATIVE AND NORMAL ALT LEVELS. (updated November 13, 2005)

·       CRYOGLOBULINEMIA IS ASSOCIATED WITH STEATOSIS AND FIBROSIS IN CHRONIC HEPATITIS C. (updated November 13, 2005)

·       CASP7 GENE POLIMORPHISMS AND FIBROSIS PROGRESSION IN CHRONIC HEPATITIS C.

·       MONITORING LIVER STIFFNESS: A NEW TOOL TO MEASURE LIVER FIBROSIS DURING THERAPY.

·       INDEPENDENT VALIDATION AND COMPARISON WITH FIBROSCAN,FIBROTEST AND LIVER BIOPSY OF CLINICAL GLYCOMICS FOR THE NON INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS C.

·       LIVER HISTOLOGY IN HEPATITIS C PATIENTS WITH NORMAL ALT LEVELS. (updated November 13, 2005)

·       OCCULT HCV INFECTION IN HEMODIALYSIS PATIENTS. (updated November 13, 2005)

·       SYSTEMATIC REVIEW OF LENGTH AND NUMBER OF PORTAL TRACTS OBTAINED WITH PERCUTANEOUS LIVER BIOPSY. (updated November 13, 2005)

·       COMBINATION OF NON INVASIVE MARKERS TO IDENTIFY LIVER FIBROSIS IN HCV PATIENTS WITH PERSISTENTLY NORMAL ALT (PNALT).

·       TRANSJUGULAR LIVER BIOPSY: HOW GOOD IS IT FOR ACCURATE HISTOLOGICAL INTERPRETATION?.

·       ANALYSIS OF ACUTE HCV INFECTION IN HIV-POSITIVE WOMEN: EVIDENCE OF INFECTION IN PBMC AND GENITAL COMPARTMENTS.

·       COMPARISON OF HCV GENOTYPE AND SUBTYPE DETERMINATION USING GLOBAL CLINICAL SAMPLES WITH THE VERSANT HCV GENOTYPING KIT, TRUGENE HCV 5’NC GENOTYPING KIT AND A NEW NS5B SEQUENCING TOOL.

·       A PROSPECTIVE ANALYSIS OF FIBROTEST-ACTITEST-FIBROSURE PROGNOSTIC VALUE IN PATIENTS WITH CHRONIC HEPATITIS C.

·       PROSPECTIVE ANALYSIS OF DISCORDANCE BETWEEN FIBROSCAN AND FIBROTEST WHEN USED IN COMBINATION AS FIRST-LINE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS C. (updated November 13, 2005)

·       GREATER PREVALENCE OF CIRRHOSIS IN HISPANICS THAN IN CAUCASIANS OR AFRICAN AMERICANS.  (updated November 14, 2005)

·       INTERNAL MEDICINE RESIDENTS KNOWLEDGE AND MANAGEMENT OF HEPATITIS C VIRUS (HCV) INFECTION IMPROVE WITH A TARGETED EDUCATIONAL INTERVENTION. (updated November 13, 2005)

·       HISPANIC RACE/ETHNICITY IS ASSOCIATED WITH AN AGGRESSIVE COURSE OF CHRONIC HEPATITIS C INFECTION: ROLE OF PATIENT DEMOGRAPHICS, HEPATIC STEATOSIS AND NECROINFLAMMATION. (updated November 13, 2005)

·       IS LIVER BIOPSY JUSTIFIED IN HEPATITIS C GENOTYPE 2 AND 3? (updated November 13, 2005)

·       IMPACT OF CAFFEINE CONSUMPTION ON SERUM ALANINE AMINOTRANSFERASE LEVEL AND HISTOLOGICAL ACTIVITY IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS C. (updated November 13, 2005)

·       HEPATITIS C VIRUS(HCV) GENOTYPE AND SUBTYPE DETERMINATION USING A NEW NS5B SEQUENCING TOOL.

·       SERUM PROTEOME PROFILE TO PREDICT VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED BY PEGYLATED INTERFERON PLUS RIBAVIRIN.

·       CUTANEOUS SIGNS OF LIVER DISEASE: VALUE FOR PROGNOSIS OF SEVERE FIBROSIS AND CIRRHOSIS. (updated November 13, 2005)

·       THE NATURAL HISTORY OF HEPATITIS C VIRUS (HCV) RECURRENCE IN PEDIATRIC LIVER TRANSPLANT

·       ACUTE HEPATITIS C: CLINICAL PRESENTATION, LABORATORY FINDINGS, AND TREATMENT OUTCOMES.

·       CHANGES IN VIRAL LOAD AND DISEASE PROGRESSION AT 5 YEARS IN A COHORT OF UNTREATED PATIENTS INFECTED WITH THE SAME STRAIN OF HCV: THE O'BRIEN PROJECT.

·       VIROLOGICAL AND HISTOLOGGICAL FEATURES OF HEPATITIS C VIRUS PATITENTS WITH NORMAL AMINOTRANSFERASE LEVELS: RESULTS OF A TEN YEAR PROPSECTIVE FOLLOW-UP STUDY.

·       HCV TREATMENT PATTERNS AND UTILIZATION FOR HCV MONO-INFECTED AND HCV/HIV COINFECTED PATIENTS IN THE VETERANS ADMINISTRATION.  (updated November 13, 2005)

·       BEHAVIOUR OF SUSTAINED RESPONDERS TO ANTI-HCV TREATMENT: MAY HCV INFECTION BE ERADICATED?

·       HEPATITIS C TREATMENT RESULTS IN AN ALASKA NATIVE / AMERICAN INDIAN POPULATION.

·       DETECTION OF MINIMAL RESIDUAL HEPATITIS C VIREMIA AT TREATMENT WEEK 12 IS ASSOCIATED WITH A HIGH PROBABILITY OF RELAPSE.

 

·       Cancer

o      INTERFERON-BASED THERAPY IN CHRONIC HEPATITIS C REDUCES CIRRHOSIS AND HEPATOCELLULAR CARCINOMA AND IMPROVES SURVIVAL: A NATION-WIDE, MULTICENTER STUDY IN TAIWAN.

o      TREATMENT OF CHRONIC HEPATITIS C VIRUS IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTS

o      ELEVATED SERUM ALPHAFETOPROTEIN PREDICTS LONG TERM PROGNOSIS IN CHRONIC HEPATITIS C: INDEPENDENT OF DEATHS RELATED TO HEPATOCELLULAR CARCINOMA.

o      MOLECULAR TRACING OF THE GLOBAL HEPATITIS C VIRUS EPIDEMIC PREDICTS REGIONAL PATTERNS OF HEPATOCELLULAR CARCINOMA MORTALITY.

o      LONG-TERM OUTCOME OF PATIENTS WITH HCV-RELATED, CHILD' S CLASS A CIRRHOSIS TREATED WITH INTERFERON–ALPHA (IFN): THE IMPACT OF SUSTAINED VIROLOGIC RESPONSE (SVR) ON HEPATOCELLULAR CARCINOMA (HCC) OCCURENCE AND MORTALITY.  (updated November 21, 2005)

o      RETREATMENT FOR NON-RESPONDERS IN INITIAL INTERFERON THERAPY SUPPRESSES HEPATOCARCINOGENESIS AND IMPROVES LONG-TERM SURVIVAL OF CHRONIC HEPATITIS C PATIENTS.

o      NEGATIVE IMPACT OF AGING ON HEPATOCARCINOGENESIS AFTER VIRAL ERADICATION IN PATIENTS WITH CHRONIC HEPATITIS C: A LONG-TERM OBSERVATION STUDY OF 1,672 PATIENTS AND AN EFFECT OF PEG-INTERFERON/RIBAVIRIN THERAPY.

o      BODY MASS INDEX INFLUENCES HEPATIC FUNCTION AND SURVIVAL PROGNOSIS IN PATIENTS WITH HCV-RELATED HEPATOCELLULAR CARCINOMA. (updated November 21, 2005)

 

·       IDU

o      RANDOMIZED TRIAL OF PEGYLATED INTERFERON FOR THE TREATMENT OF ACUTE HCV IN SEATTLE INJECTION DRUG USERS.

o      NATURAL HISTORY OF HEPATITIS C VIRUS INFECTION AMONG INJECTION USERS IN VANCOUVER, CANADA.

 

·       Psychiatric Issues

o      COMBINATION THERAPY USING PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH PSYCHIATRIC ILLNESSES.

o      INTERFERON THERAPY COMPLETION AND RESPONSE RATES FOR HEPATITIS C AMONG PATIENTS WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, AND SUBSTANCE USE DISORDERS.

 

 

Diagnostic Tools

Information about various diagnostic tools used to treat and manage hepatitis C including liver biopsy, and non-invasive tests that measure liver health and disease.

 

 

·        Liver Imaging Modalities / Public Policy, Epidemiology, and Decision Analysis

o      VALIDATION OF AN MRI TECHNIQUE TO MEASURE LIVER FAT CONTENT. (updated Nov 12, 2005)

o      AMOUNT AND TYPE OF LIVER FIBROSIS DETECTED BY STIFFNESS MEASUREMENTS.

o      ASSESSMENT OF HEPATIC FIBROSIS IN CHRONIC LIVER DISEASE — USEFULNESS OF THE STRAINRATE IMAGING METHOD

o      PROSPECTIVE RANDOMISED COMPARISON OF MINI-LAPAROSCOPY AND PERCUTANEOUS LIVER BIOPSY. ANALYSIS OF 1000 EXAMINATIONS. DIAGNOSIS OF CIRRHOSIS AND COMPLICATIONS.

o      PREVALENCE AND FACTORS ASSOCIATED WITH FAILURE OF LIVER STIFFNESS MEASUREMENT USING FIBROSCAN® IN A PROSPECTIVE STUDY OF 2114 EXAMINATIONS. (updated Nov 12, 2005)

o      NON-INVASIVE DETECTION OF CELLULAR PROLIFERATION IN THE WOODCHUCK MODEL OF HEPATOCELLULAR CARCINOMA.

o      ADMINISTRATION OF ERYTHROPOIETIN FOR HEPATITIS C TREATMENT-RELATED ANEMIA IS NOT COST EFFECTIVE. (updated Nov 12, 2005)

o      HIV TESTING AND HIV SEROPOSITIVITY AMONG PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: MISSED OPPORTUNITIES FOR EARLY DIAGNOSIS. (updated Nov 12, 2005)

o      COFFEE DRINKING DECREASES THE RISK OF CHRONIC LIVER DISEASE IN THE UNITED STATES POPULATION. (updated Nov 12, 2005)

o      THE COST OF VARICEAL BLEEDING IN CIRRHOSIS - A COMPARISON OF A DECISION BASED ECONOMIC MODEL AND PATIENT DATA.  (updated Nov 12, 2005)

o      IMPACT OF PATIENT RACE AND GENDER ON THE CARE OF A LARGE COHORT OF COMMUNITY BASED HEPATITIS C PATIENTS. (updated Nov 12, 2005)

o      COST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HEPATITIS C INFECTION IN PATIENTS COINFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (updated Nov 12, 2005)

o      TREATMENT ALTERNATIVES FOR HEPATITIS B CIRRHOSIS: A COST-EFFECTIVENESS ANALYSIS.

o      THE ROLE OF LIVER BIOPSY FOR ASYMPTOMATIC LIVER ENZYME ELEVATION. (updated Nov 12, 2005)

o      PSYCHOSOCIAL FACTORS IN LIVER TRANSPLANTATION: HOW ARE U.S. CENTERS EVALUATING THEM. (updated Nov 12, 2005)

o      REAL TIME ULTRASOUND GUIDED LIVER BIOPSY IN REAL LIFE; A COMPARISON OF PRE-BIOPSY VERSUS REAL TIME ULTRASOUND. (updated Nov 12, 2005)

o      INFORM CONSENT FOR CLINICAL TRIALS- STILL SOME WAY TO GO. (updated Nov 12, 2005)

o      METHODOLOGICAL ISSUES IN COST EFFECTIVENESS EVALUATION OF HEPATITIS A VACCINE: A SYSTEMATIC REVIEW (updated Nov 12, 2005)

o      QUALITY-OF-LIFE TRADOFFS FOR HEPATITIS C TREATMENT: DO PATIENTS AND HEALTH PROFESSIONALS AGREE? (updated Nov 12, 2005)

 

 

Epidemiology

Studies that report HCV prevalence and/or trends in the general population as well as in special populations or groups. 

 

·       CURRENT EPIDEMIOLOGICAL TRENDS AND OUTCOME IN A LARGE COHORT OF ACUTE HEPATITIS C PATIENTS. (updated November 13, 2005)

·       PREVALENCE OF DIABETES MELLITUS AND INSULIN RESISTANCE IN JAPANESE PATIENTS WITH CHRONIC HEPATITIS C. (updated November 14, 2005)

·       ANALYSIS OF THE HCV GENOTYPE 5A MOLECULAR EPIDEMIOLOGY IN BELGIUM USING A BAYESIAN APPROACH.

·       A SYSTEMATIC REVIEW OF PANELS OF SURROGATE NON-INVASIVE MARKERS OF LIVER FIBROSIS IN HEPATITIS C. (updated November 13, 2005)

·       OUTBREAK OF HEPATITIS C VIRUS INFECTION DURING SCLEROTHERAPY OF VARICOSE VEINS: LONG-TERM FOLLOW-UP OF 160 PATIENTS (3775 PATIENT-YEARS). (updated November 13, 2005)

·       SEXUAL DYSFUNCTION IS HIGHLY PREVALENT AMONG MEN WITH CHRONIC HEPATITIS C VIRUS INFECTION AND NEGATIVELY IMPACTS HEALTH-RELATED QUALITY OF LIFE. (updated November 13, 2005)

·       SELF-REPORTED HEPATITIS C VIRUS ANTIBODY STATUS AND RISK BEHAVIOR IN YOUNG INJECTORS. (updated November 13, 2005)

·       RACIAL DISPARITIES IN HEPATITIS C TESTING.

·       PREVALENCE OF RISK FACTORS FOR HCV TRANSMISSION IN HIV INFECTED AND HIV/HCV CO-INFECTED PATIENTS.  (updated November 18, 2005)

·       ALCOHOL USE IN US VETERANS: A MULTICENTER STUDY OF 4,061 HEPATITIS C-INFECTED PATIENTS. (updated November 13, 2005)

·       PREVALENCE AND CHARACTERISTICS OF HEPATITIS C VIRUS INFECTION IN A POPULATION OF PATIENTS WITH SICKLE CELL DISEASE AT A TERTIARY CARE TEACHING HOSPITAL (updated November 13, 2005)

·       HOW PLACE OF RESIDENCE AND DISTANCE TO MEDICAL CARE INFLUENCE HEPATITIS C (HC) DETECTION : A POPULATION-BASED STUDY.

·       CHANGING EPIDEMIOLOGY OF HCV AND HBV INFECTIONS IN NORTHERN ITALY: A SURVEY IN THE GENERAL POPULATION. (updated November 13, 2005)

·       DISPARITIES IN THE CLINICAL CHARACTERISTICS, EVALUATION AND OUTCOMES OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS WITH HEPATITIS C. (updated November 13, 2005)

·       HOW WELL INFORMED ARE HCV-INFECTED GERMAN SUBJECTS ABOUT THEIR DISEASE AND HOW DO THEY PERCEIVE THE PUBLIC INFORMATION STATUS ABOUT HEPATITIS C. (updated November 13, 2005)

·       HEPATITIS B AND C: PREVALENCE AND SOCIAL FACTORS ASSOCIATED WITH SERO-POSITIVITY AMONG CHILDREN IN KARACHI, PAKISTAN. (updated November 13, 2005)

·       FACTORS ASSOCIATED WITH THE PRESENCE OF HEPATITIS C (HCV) RNA AMONG ANTI-HCV POSITIVE YOUNG INJECTING DRUG USERS (IDUS) IN METROPOLITAN CHICAGO. (updated November 13, 2005)

·       COMPARATIVE MOLECULAR ANALYSIS OF HVR1 AND HVR2 TO DETECT TRANSMISSION OF HCV GENOTYPE 2 FROM AN ANESTHESIOLOGIST TO 32 PATIENTS.

·       FIVE MILLION AMERICANS INFECTED WITH THE HEPATITIS C VIRUS: A CORRECTED ESTIMATE. (updated November 21, 2005)

·       EVIDENCE FOR SEXUAL TRANSMISSION OF HCV IN RECENT EPIDEMIC IN HIV-INFECTED MEN IN SOUTH-EAST ENGLAND.

·       CAUSES OF DEATH IN PEOPLE WITH HEPATITIS B OR C INFECTION: A POPULATION BASED COHORT STUDY.

·       MASS SCREENINGS IN NEW YORK CITY REVEAL HIGH PREVALENCE OF HEPATITIS B IN AN URBAN ASIAN POPULATION.

·       COMPARATIVE EPIDEMIOLOGY OF HEPATITIS C AND HEPATITIS B IN MANITOBA, CANADA.

·       HEPATITIS C VIRUS GENOTYPES AND VIRAL CONCENTRATIONS IN PARTICIPANTS FROM A GENERAL POPULATION SURVEY IN THE UNITED STATES.

·       CAUSES OF DEATH IN PEOPLE WITH HEPATITIS B OR C INFECTION: A POPULATION BASED COHORT STUDY (updated November 21, 2005)

 

 

HIV/HCV Coinfection

This section lists all of the studies released at AASLD about HIV/HCV coinfection.

 

·       Diagnosis

o      HIV TESTING AND HIV SEROPOSITIVITY AMONG PATIENTS WITH CHRONIC HEPATITIS C VIRUSINFECTION: MISSED OPPORTUNITIES FOR EARLY DIAGNOSIS.

o      FACTORS ASSOCIATED WITH LIVER CLINIC REFERRAL OF HEPATITIS C VIRUS (HCV)-INFECTED PATIENTS.

o      CROSS-REACTIVE EPITOPES IDENTIFIED IN HEPATITIS C VIRUS E1E2 PROTEINS INDUCE ANTIBODIESTHAT CAPTURE VIRIONS FROM INFECTED PATIENTS’ SERA AND INHIBIT HCV/HIV PSEUDO VIRUS ENTRYINTO SUSCEPTIBLE CELLS.

o      DIAGNOSIS OF HEPATIC FIBROSIS AND CIRRHOSIS BY LIVER STIFFNESS MEASUREMENT IN HIV-HCV CO-INFECTED PATIENTS: A PROSPECTIVE STUDY.

 

 

·       HCV Treatment

o      IMPACT OF HCV THERAPY VS. NO TREATMENT IN THE PROGRESSION OF FIBROSIS IN PATIENTS THAT ARE COINFECTED WITH HIV.

o      TREATMENT OF HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS COINFECTION : FROM LARGE TRIALS TO REAL LIFE.

o      HEPATIC STEATOSIS IN PATIENTS WITH HIV-HCV CO-INFECTION ENROLLED IN THE AIDS PEGASYS RIBAVIRIN INTERNATIONAL CO-INFECTION TRIAL (APRICOT): CLINICAL CHARACTERISTICS AND RESPONSE TO TREATMENT.

o      EARLY RIBAVIRIN IMPROVES SUSTAINED VIROLOGICAL RESPONSES IN ACUTE HCV INFECTION IN HIV POSITIVE INDIVIDUALS.

o      MODELING RIBAVIRIN PHARMACOKINETICS IN HIV-1/HCV-COINFECTED PATIENTS PREDICTS HIGHER INTRACELLULAR RIBAVIRIN CONCENTRATION IN SUSTAINED VIRAL RESPONDERS.

o      PHARMACODYNAMIC EFFECTS OF PEGYLATED INTERFERON-ALPHA2B DIFFERENTIATE SUSTAINED VIROLOGIC RESPONDERS FROM NONRESPONDERS IN HEPATITIS C VIRUS/HUMAN IMMUNODEFICIENCY VIRUS COINFECTED PATIENTS.

o      SAFETY AND EFFICACY OF 24-WEEK COURSE OF PEGYLATED INTERFERON-ƒÑ2A AND RIBAVIRIN FOR THE TREATMENT OF ACUTE HCV INFECTION IN HIV POSITIVE PATIENTS.

o      DOES TYPE AND DURATION OF ANTIRETROVIRAL THERAPY ATTENUATE LIVER FIBROSIS IN HIV/HCV COINFECTED PATIENTS?  (updated November 13, 2005)

o      HCV TREATMENT PATTERNS AND UTILIZATION FOR HCV MONO-INFECTED AND HCV/HIV COINFECTED PATIENTS IN THE VETERANS ADMINISTRATION.

o      PEGINTERFERON ALFA-2B PLUS RIBAVIRIN VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C IN HIV-COINFECTED PATIENTS (updated November 16, 2005)

o       

 

 

·       Natural History

o      SEVERE IMPAIRMENT IN QUALITY OF LIFE IN HIV POSITIVES WITH HEPATITIS C BUT NOT WITH HEPATITIS B.

o      INTRAHEPATIC CD8-MEDIATED KILLING IS THE PROBABLE CAUSE OF PROGRESSIVE LIVER DAMAGE IN HCV/HIV COINFECTED PATIENTS

o      HIV INCREASES THE FORMATION AND ACTIVATION OF MACROPHAGE RESERVOIRS OF HCV IN COINFECTED PATIENTS.

o      ANALYSIS OF CD1D-DEPNDENT NKT FUNCTION IN SUBJECTS WITH HCV VERSUS HIV/HCV INFECTION

o      HIV/HCV COINFECTED PATIENTS DISPLAY INCREASED PERISINUSOIDAL HEPATIC STELLATE CELL ACTIVATION AND LESS INFLAMMATORY ACTIVITY.

o      HCV-SPECIFIC T-CELL RESPONSES OF ACUTELY HCV INFECTED INDIVIDUALS WITH AND WITHOUT HIV

o      PREDICTIVE FACTORS IN THE TREATMENT OF ACUTE HCV-INFECTION IN HIV-POSITIVE INDIVIDUALS – INTERIM ANALYSIS OF A LARGE GERMAN MULTICENTER STUDY

o      SUSTAINED VIROLOGIC RESPONSE (SVR) TO RETREATMENT WITH IFN ALFACON 1 + RIBAVIRIN IN HCV/HIV COINFECTED PATIENTS WHO HAD FAILED 12 WEEKS OF PEG IFN ALPHA 2 + RIBAVIRIN THERAPY